Exome Dataset Expands to Whole Genome

Members of the Exome Aggregation Consortium launch the Genome Aggregation Database.

By | October 19, 2016

With information from 126,216 human exomes and 15,136 whole human genomes, the Genome Aggregation Database (gnomAD), hosted by the Broad Institute of MIT and Harvard, has launched in beta. Members of the Exome Aggregation Consortium (ExAC), the leaders of gnomAD, have accumulated nearly “40 terabytes of raw variant data that need to be parsed for analysis,” co-principal investigator Daniel MacArthur of the Broad announced today (October 19) at the American Society for Human Genetics (ASHG) annual meeting, held in Vancouver this week. 
 
Altogether, the gnomAD team is now looking at 17.7 million variants identified from exome data and 254.2 million variants pulled from whole-genome data. 
 
Already, the expansion from ExAC to gnomAD has demonstrated “the benefits of looking at whole-genome data in addition to exome-sequencing data,” MacArthur said, inviting meeting attendees to access the publicly available database. 
 
The gnomAD dataset currently contains single-nucleotide polymorphism (SNP) and insertion-deletion (indel) data. The gnomAD team, which includes more than 100 PIs, will next be analyzing copy-number variants (CNVs), among other things, MacArthur said.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham